glp 1 agonists and inflammation Anti-inflammatory role of glucagon-like peptide receptor its clinical implications Beyond metabolic benefits: The underexplored

It tracks into adult cardiometabolic disease, carries psychosocial burden, and responds poorly to lifestyle intervention alone in many patients

[DOI] [PubMed] [Google Scholar] 12.Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, Tselepis AD, Elisaf MS

Glucagon-like Peptide-1 (GLP-1) Agonists Market Summary The GLP-1 agonists market in the 7MM is projected to grow at a significant CAGR by 2036 in leading countries (US, EU4, UK and Japan)

For answers, we turned to Terry Dubrow, MD, who has spent the last 18 months studying and testing retatrutide and other GLP-1 medications

doi: 10.1136/bmj.l4898 7 TanZHuangSMeiKLiuMMaJJiangYet al